Sumate Kunching . The effect of atorvastatin on macular pigment optical density: experimental study. (). Mae Fah Luang University. Learning Resources and Educational Media Center. : , .
The effect of atorvastatin on macular pigment optical density: experimental study
Abstract:
Introduction: Low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)
cholesterol are serum lipoproteins involved in the transportation of lutein and
zeaxanthin to the retina to serve as macular pigments (MPs). Atorvastatin, a serum
cholesterol-lowering agent, can affect the MP distribution and reduce macular pigment
optical density (MPOD). MPOD is one of the best indicators of retinal diseases such as
age-related macular degeneration. Objective: To study the effect of atorvastatin on the
level of MPOD in people taking atorvastatin 10 mg for more than 6 months.
Methodology: An experimental study was conducted on 44 Asian men and women,
aged between 30 and 60 years and residing in Thailand, who were recruited and
divided into two equal groups. The first group was currently taking atorvastatin 10 mg
for at least 6 months, whereas the control group did not receive atorvastatin. MPOD
was measured in all participants using the macular pigment screener-II. Participants
were required to sign an informed consent form and complete questionnaires regarding
various factors that may influence the MPOD. Data were analyzed using the
KolmogorovSmirnov test and t-test to compare the MPOD between groups. Results:
The mean MPOD of the experiment group was 0.3295 ± 0.1311 DU, whereas that of
the control group was 0.4686 ± 0.1491 DU. The mean MPOD of the experimental
group was significantly lower than that of the control group (p-value = 0.002).
Conclusion: Patients taking atorvastatin had a lower MPOD than those who did not.
Mae Fah Luang University. Learning Resources and Educational Media Center
Address:
CHIANG RAI
Email:
library@mfu.ac.th
Modified:
2022-09-29
Issued:
2022-09-29
บทความ/Article
application/pdf
Journal of Health Science and Alternative Medicine (2021) Vol.3 (3): 1-6